Book contents
- Frontmatter
- Contents
- List of contributors
- Part I Introduction
- Part II Clinical background and research design
- 2 From pharmacogenetics to pharmacogenomics of psychotropic drug response
- 3 Neuropsychopharmacology: the interface between genes and psychiatric nosology
- 4 Methodological issues in psychopharmacogenetics
- 5 Statistical approaches in psychopharmacogenetics
- Part III Molecular background
- Part IV Pharmacokinetics
- Part V Specific psychotropic drugs and disorders
- Part VI Pharmacogenetics and brain imaging
- Part VII Industry perspectives
- Index
4 - Methodological issues in psychopharmacogenetics
from Part II - Clinical background and research design
Published online by Cambridge University Press: 20 August 2009
Edited by
Book contents
- Frontmatter
- Contents
- List of contributors
- Part I Introduction
- Part II Clinical background and research design
- 2 From pharmacogenetics to pharmacogenomics of psychotropic drug response
- 3 Neuropsychopharmacology: the interface between genes and psychiatric nosology
- 4 Methodological issues in psychopharmacogenetics
- 5 Statistical approaches in psychopharmacogenetics
- Part III Molecular background
- Part IV Pharmacokinetics
- Part V Specific psychotropic drugs and disorders
- Part VI Pharmacogenetics and brain imaging
- Part VII Industry perspectives
- Index
Summary
This chapter discusses methodological issues relevant to conducting pharmacogenetic studies in clinical psychopharmacology. First, basic pharmacologic principles are reviewed, followed by a discussion of the drug development process. In addition to aiding in the drug discovery process, pharmacogenetic finding would also help with the signal:noise problem, at the human testing phase of drug development (that is, phase I through III). Scientists can select the specific subset of the population (that is, those with the genetic variant) likely to respond to the drug. The chapter reviews the significant potential for advancing psychiatric drug development as a result of improved understanding of the pharmacogenetics and pharmacogenomics relevant to the effects of drugs on the human brain. Last, the research linking cytochrome P-450 CPY2D6 poor metabolizers with increased risk of toxicity on routine doses of tricyclic antidepressants (TCAs) are reviewed as an example of the methodological issues encountered when conducting such studies.
Keywords
- Type
- Chapter
- Information
- Pharmacogenetics of Psychotropic Drugs , pp. 57 - 71Publisher: Cambridge University PressPrint publication year: 2002